Jupiter Topco LLC acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 212,346 shares of the insurance provider's stock, valued at approximately $84,347,000. Jupiter Topco LLC owned approximately 0.18% of Humana at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the stock. J. Goldman & Co LP acquired a new stake in shares of Humana during the 2nd quarter worth $258,000. EFG International AG acquired a new position in Humana in the second quarter valued at about $56,000. Ancora Advisors LLC acquired a new position in Humana in the second quarter valued at about $97,000. Redwood Grove Capital LLC bought a new stake in Humana during the second quarter worth about $23,464,000. Finally, Primecap Management Co. CA acquired a new stake in Humana during the second quarter worth about $3,674,000. 92.38% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have commented on HUM shares. TD Cowen raised their target price on shares of Humana from $350.00 to $370.00 and gave the company a "hold" rating in a report on Friday, July 31st. Piper Sandler raised shares of Humana from a "hold" rating to an "overweight" rating and set a $463.00 price target for the company in a report on Thursday, July 30th. Sanford C. Bernstein reiterated an "outperform" rating and set a $425.00 price target on shares of Humana in a research report on Wednesday, June 3rd. Evercore raised shares of Humana from an "in-line" rating to an "outperform" rating and set a $480.00 price objective on the stock in a research note on Wednesday, July 29th. Finally, Zacks Research downgraded shares of Humana from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 11th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $403.91.
Get Our Latest Stock Report on Humana
Humana Stock Up 0.1%
Shares of NYSE HUM opened at $390.06 on Thursday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The company has a market cap of $46.84 billion, a price-to-earnings ratio of 36.90, a PEG ratio of 2.22 and a beta of 0.72. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88. The stock has a 50-day moving average price of $384.44 and a two-hundred day moving average price of $286.38.
Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The business's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.27 earnings per share. As a group, analysts forecast that Humana Inc. will post 9.12 earnings per share for the current fiscal year.
Humana Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
